BRIEF—FUJIFILM Diosynth completes UK facility

Japanese contract development and manufacturing organization FUJIFILM Diosynth Biotechnologies today announced the successful completion of a new facility in Darlington, UK, which is now cGMP operational for manufacturing of viral gene therapies, oncolytic viruses and viral vaccines for clinical trials.

This milestone underscores the company’s investment in and commitment to meeting the increased demand for the production of early-stage clinical trial (first-in-human) investigational viral vector products.

“We are excited to continue working with our biopharmaceutical partners, including early-stage companies, to help them bring new gene therapies to market, which hold tremendous promise in revolutionizing treatment options for patients,” said Jonathan Haigh, head of UK site at FUJIFILM Diosynth Biotechnologies UK.

“Our advanced therapy integrated network, including an ongoing commercial viral gene therapy expansion in nearby Billingham, UK, allows customers to benefit from our end-to-end cell and gene therapy services provided by our highly skilled workforce,” he added.